The CMC section — Chemistry, Manufacturing and Controls — is where a regulator decides whether your peptide can be made consistently and safely. It is also where many IND timelines slip. Knowing what it must contain, and starting it early, keeps your filing on track.
What is CMC?
CMC documents how your drug substance and drug product are made, characterized, controlled and kept stable. For a peptide IND, it tells the regulator that you understand your molecule and can produce it reproducibly to a defined specification under GMP.
What the peptide CMC section covers
- Drug substance: the manufacturing process, route and controls for the peptide API.
- Characterization: identity, structure and confirmation of the molecule.
- Specifications: purity, impurity limits, content and identity criteria with justification.
- Analytical methods: the (validated) methods used to test against those specifications.
- Impurities: identification and control, building on impurity control.
- Stability: data supporting storage conditions and dating.
- Drug product: formulation, manufacture and controls of the finished product.
Key point: CMC is a story about control. Every specification needs a justification, and every claim needs data. Gaps read as risk to a reviewer.
Common reasons CMC stalls
Most CMC delays trace to thin characterization, unjustified specifications, or analytical methods that were never properly validated. Because CMC depends on real manufacturing and analytical data, it cannot be written the week before filing — it is assembled across development.
How to get it right
Start CMC early, generate the data deliberately, and work with a manufacturer who builds the documentation as they go. A CDMO experienced in peptide APIs will supply the process descriptions, validated methods and stability data your CMC needs — the practical payoff of choosing the right partner, as covered in how to choose a peptide CDMO.